Etelcalcitide (Parsabiv®) is indicated for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on haemodialysis.
|Rapid Review Process||Complete|
|Rapid review received||14/06/2017|
|Rapid review completed||01/09/2017|
|Rapid Review outcome||Full pharmacoeconomic assessment recommended at the submitted price|
The HSE has approved reimbursement following confidential price negotiations; April 2018.